CombiPatch is indicated in women with an intact uterus for the treatment of moderate to severe vasomotor symptoms and symptoms of vulvar and vaginal atrophy that are associated with menopause. It is also indicated for treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure.
Minivelle is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause and for the prevention of postmenopausal osteoporosis.
CombiPatch is available as 0.05/0.14mg per day and 0.05/0.25mg per day strengths in cartons containing 8 systems each. Minivelle is available as 0.025mg per day, 0.0375mg per day, 0.05mg per day, 0.075mg per day, and 0.1mg per day strengths in patient calendar packs of 8 systems.
For more information call (800) 455-8070 or visit Noven.com.